Candel Therapeutics (CADL) Other Non-Current Liabilities (2020 - 2025)

Candel Therapeutics' Other Non-Current Liabilities history runs 6 years deep, the most recent figure standing at $15.6 million for Q4 2025.

• In Q4 2025, Other Non-Current Liabilities changed N/A year-over-year to $15.6 million; the TTM figure through Dec 2025 stood at $15.6 million (changed N/A YoY), while the FY2025 annual figure was $15.6 million, changed N/A from the prior year.
• Other Non-Current Liabilities came in at $15.6 million for Q4 2025 at Candel Therapeutics, down from $15.9 million in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $27.4 million in Q3 2021 to a low of $433000.0 in Q3 2023.
• A 5-year average of $9.1 million and a median of $5.0 million in 2022 frame the typical range for Other Non-Current Liabilities.
• Across the five-year window, Other Non-Current Liabilities sank 90.64% in 2023 and surged 3568.82% in 2024, its largest moves.
• Candel Therapeutics' Other Non-Current Liabilities stood at $18.3 million in 2021, then tumbled by 89.69% to $1.9 million in 2022, then plunged by 51.33% to $916000.0 in 2023, then soared by 1634.28% to $15.9 million in 2024, then slipped by 1.81% to $15.6 million in 2025.
• According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $15.6 million, $15.9 million, and $14.2 million for Q4 2025, Q3 2024, and Q2 2024 respectively.

Peer Comparison